Skip to main content
Skip to main content
NOVT logo

Novanta Inc. (NOVT)

$165.08 +$3.36 (+2.08%) |Fair · 64
Bottom line: BUY — our Council read (64/100) and AI Score (64/100) broadly agree.
MCap: $5.88B| P/E Ratio: 85.9| Vol: 236.1K| Target: $150.00 (-9.1%)| 52-wk range: $98.27 – $171.85
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Novanta Inc. (NOVT) trades at $165.08 with AI Score 64/100 (Grade B+). Novanta Inc. designs, manufactures, and sells precision components and subsystems for medical and industrial OEMs worldwide. Market cap: $5.88B, Sector: Technology.

Price live · AI analysis from May 10, 2026
Novanta Inc. designs, manufactures, and sells precision components and subsystems for medical and industrial OEMs worldwide. The company operates through Photonics, Vision, and Precision Motion segments, serving diverse applications from laser processing to medical imaging.

NOVT stock analysis for 2026: Analysts have set a consensus price target of $150.00 for Novanta Inc., suggesting 9.1% downside from the current price of $165.08. The AI MoonshotScore is 64/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Council Score · Weighted Average of 3 Disciplines
BUY 64/100 · B+

NOVT: 1/1 perspectives are bullish.

How is this calculated? →
Council Score · 8 perspectives · See tabs for details →

Novanta Inc. (NOVT) Technology Profile & Competitive Position

CEOMatthijs Glastra
Employees3000
HeadquartersBedford, MA, US
IPO Year1999

Novanta Inc. is a technology company providing precision components and subsystems to original equipment manufacturers in the medical and industrial sectors. With a focus on photonics, vision, and precision motion, Novanta serves a global market, leveraging its diverse brand portfolio and direct sales channels.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 10, 2026

What Is the Investment Thesis for NOVT?

Novanta Inc. presents a notable research candidate driven by its diversified product portfolio and exposure to high-growth medical and industrial markets. The company's focus on precision components and subsystems positions it favorably within the technology sector. With a market capitalization of $5.88B and a P/E ratio of 85.9, Novanta's valuation reflects its growth potential. Key catalysts include expanding applications in medical imaging and industrial automation. Potential risks include economic downturns affecting OEM demand and competition from established players. The company's gross margin of 44.4% indicates strong pricing power. Investors should monitor revenue growth and profitability trends to assess long-term value.

Based on FMP financials and quantitative analysis

NOVT Key Highlights

  • Market Cap of $5.88B reflects investor confidence in Novanta's growth prospects.
  • P/E ratio of 85.9 indicates a premium valuation, suggesting high growth expectations.
  • Gross Margin of 44.4% demonstrates strong pricing power and efficient cost management.
  • Profit Margin of 5.5% indicates profitability, with potential for expansion through operational efficiencies.
  • Beta of 1.65 suggests higher volatility compared to the market, reflecting growth stock characteristics.

Who Are NOVT's Competitors?

NOVT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
VICR Vicor Corporation $290.13 +2.54% $13.09B 95
ESE ESCO Technologies Inc. $340.51 +2.32% $8.82B 79
PLXS Plexus Corp. $277.10 +0.72% $7.41B 70
ST Sensata Technologies Holding plc $46.20 +1.91% $6.72B 59
BDC Belden Inc. $115.79 +0.33% $4.51B 63
MDA Macdonald Dettwiler & Associate $42.11 +3.34% 6B 66
WATT Energous Corporation $19.29 -19.93% $28.65M 65
SELX Selecta Biosciences, Inc. $0.34 +580.00% $12.78M 64

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NOVT's Key Strengths?

  • Diversified product portfolio across photonics, vision, and precision motion.
  • Strong presence in high-growth medical and industrial markets.
  • Established relationships with major OEMs.
  • Proprietary technologies and intellectual property.

What Are NOVT's Weaknesses?

  • High P/E ratio may indicate overvaluation.
  • Reliance on OEM demand, which can be cyclical.
  • Exposure to global economic conditions.
  • Profit margin could be higher.

What Could Drive NOVT Stock Higher?

  • New product launches in medical imaging technologies expected in Q3 2026, potentially driving revenue growth.
  • Increasing demand for automation solutions in industrial markets, benefiting Novanta's precision motion segment.
  • Expansion of applications in DNA sequencing and life science research, creating opportunities for the photonics segment.
  • Strategic acquisitions to expand product offerings and market reach.

What Are the Key Risks for NOVT?

  • Rich valuation — a P/E of 85.9 runs well above the Technology sector’s ~38x, leaving little room for a miss.
  • Economic downturns affecting OEM spending, which could reduce demand for Novanta's products.
  • Competition from established players and new entrants, potentially impacting market share.
  • Technological obsolescence, requiring continuous investment in R&D.
  • Supply chain disruptions, which could affect production and delivery schedules.
  • High P/E ratio may indicate overvaluation, making the stock vulnerable to market corrections.

What Are the Growth Opportunities for NOVT?

  • Expanding Medical Imaging Applications: The increasing demand for advanced medical imaging technologies presents a significant growth opportunity for Novanta. As healthcare providers adopt more sophisticated diagnostic and surgical tools, Novanta's vision segment, offering medical-grade technologies and visualization solutions, is well-positioned to benefit. This market is projected to grow, driven by an aging population and advancements in medical technology. Novanta can leverage its existing relationships with medical OEMs to expand its market share and introduce new products tailored to emerging imaging modalities.
  • Penetrating Industrial Automation Market: The global industrial automation market is experiencing rapid growth, driven by the need for increased efficiency and productivity. Novanta's precision motion segment, offering encoders, motors, and motion control solutions, is strategically aligned to capitalize on this trend. By providing components for robotics and automated systems, Novanta can tap into a market projected to reach billions of dollars in the coming years. Focusing on solutions that enhance precision and reliability will be crucial for capturing market share.
  • Leveraging Photonics in Industrial Processing: The photonics segment can capitalize on the increasing use of lasers in industrial processing applications, such as cutting, welding, and marking. The demand for high-precision laser systems is growing across various industries, including automotive, electronics, and aerospace. Novanta's portfolio of CO2, solid-state, and ultrafast lasers positions it to meet this demand. Investing in R&D to develop more efficient and versatile laser technologies will be key to maintaining a competitive edge.
  • Expanding into DNA Sequencing Technologies: The advancements in DNA sequencing technologies are creating new opportunities for Novanta's photonics and vision segments. As the cost of sequencing decreases and the applications expand, the demand for high-performance optical components and imaging systems is expected to grow. Novanta can leverage its expertise in these areas to develop solutions tailored to the specific needs of DNA sequencing equipment manufacturers. Collaborating with research institutions and biotech companies can accelerate the development and adoption of these technologies.
  • Developing Integrated Robotic End-of-Arm Solutions: The market for robotic end-of-arm tooling is expanding as manufacturers seek to automate complex tasks. Novanta's precision motion segment can capitalize on this trend by developing integrated solutions that combine motors, encoders, and control systems. These solutions can enhance the performance and flexibility of robotic systems, making them suitable for a wider range of applications. Focusing on ease of integration and customization will be crucial for attracting customers in this market.

What Opportunities Does NOVT Have?

  • Expanding applications in medical imaging and diagnostics.
  • Increasing adoption of automation in industrial processes.
  • Growth in DNA sequencing and life science research.
  • Strategic acquisitions to expand product offerings and market reach.

What Threats Does NOVT Face?

  • Competition from established players and new entrants.
  • Technological obsolescence.
  • Economic downturns affecting OEM spending.
  • Supply chain disruptions.

What Are NOVT's Competitive Advantages?

  • Specialized Product Portfolio: Novanta offers a range of specialized and high-precision components that are critical for its customers' applications.
  • Strong Brand Recognition: The company's various brands, such as Cambridge Technology and Synrad, are well-recognized in their respective markets.
  • Established Customer Relationships: Novanta has long-standing relationships with major OEMs in the medical and industrial sectors.
  • Technological Expertise: The company's focus on photonics, vision, and precision motion requires significant technical expertise and R&D investment.

What Does NOVT Do?

Founded in 1968 and headquartered in Bedford, Massachusetts, Novanta Inc. has evolved from its origins as GSI Group, Inc. to become a key provider of technology solutions for original equipment manufacturers (OEMs) in the medical and industrial markets. The company operates through three primary segments: Photonics, Vision, and Precision Motion. The Photonics segment offers laser scanning, beam delivery, CO2 lasers, solid-state lasers, ultrafast lasers, and optical light engines, catering to industrial processing, metrology, medical imaging, DNA sequencing, and medical laser procedures. The Vision segment provides medical-grade technologies, including insufflators, pumps, visualization solutions, wireless technologies, video recorders, optical data collection, and machine vision technologies. The Precision Motion segment delivers optical and inductive encoders, precision motors, servo drives, motion control solutions, integrated stepper motors, robotic end-of-arm technology, air bearings, and air bearing spindles. Novanta sells its products through a direct sales force, resellers, distributors, and system integrators, utilizing brand names such as Cambridge Technology, Synrad, and Celera Motion. This diversified approach allows Novanta to maintain a strong presence in its target markets.

What Products and Services Does NOVT Offer?

  • Designs and manufactures photonics-based solutions, including lasers and optical light engines.
  • Provides medical-grade technologies such as insufflators, pumps, and visualization solutions.
  • Offers precision motion components like encoders, motors, and servo drives.
  • Develops and sells wireless technologies and video integration solutions for operating rooms.
  • Creates optical data collection and machine vision technologies.
  • Provides solutions for industrial processing, metrology, and medical imaging.
  • Offers embedded touch screen solutions and thermal chart recorders.

How Does NOVT Make Money?

  • Sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers (OEMs).
  • Generates revenue through direct sales, resellers, distributors, and system integrators.
  • Offers a diverse product portfolio across medical and industrial markets.
  • Focuses on providing high-precision and reliable components for specialized applications.

What Industry Does NOVT Operate In?

Novanta Inc. operates in the hardware, equipment, and parts industry within the broader technology sector. This industry is characterized by continuous innovation, increasing automation, and demand for precision components. The medical and industrial markets, which Novanta serves, are experiencing growth driven by technological advancements and increasing healthcare spending. Competition includes companies like Vicor Corporation (VICR) and Sensata Technologies Holding plc (ST), each vying for market share through product differentiation and strategic partnerships. Novanta's focus on photonics, vision, and precision motion positions it to capitalize on these trends.

Who Are NOVT's Key Customers?

  • Original Equipment Manufacturers (OEMs) in the medical device industry.
  • OEMs in the industrial automation and processing sectors.
  • Healthcare providers utilizing medical imaging and surgical equipment.
  • Companies involved in DNA sequencing and life science research.
AI Confidence: 72% Updated: May 10, 2026

How Novanta Inc. Is Valued

Novanta Inc. carries a market capitalization of $5.88B, placing it in the mid-cap category. Relative to its peer group, NOVT's quantitative score of 64/100 is roughly in line with the peer average of 73/100.

Company Profile

Novanta Inc. operates in the Hardware, Equipment & Parts industry within the Technology sector. It is headquartered in Bedford, US. The company is led by CEO Matthijs Glastra. NOVT has traded publicly since 1999.

ROE 5%Key Financial Metrics

Return on equity for Novanta Inc. stands at 5.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.0%, showing how much profit it generates from its asset base. NOVT trades at a trailing price-to-earnings ratio of 85.87, above the Technology sector average of ~38x. Its free cash flow yield is 1.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.56 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.8%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 6/9Financial Health

Novanta Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.44 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Novanta Inc. revenue of about $1.05B for fiscal 2026, with EPS near $3.59.

NOVT Financials

Fundamental Snapshot

Revenue Growth (FY)
+3.3%
Net Income Growth (FY)
-16.0%
EPS Growth (FY)
-17.4%
Free Cash Flow Growth (FY)
-65.7%
P/E (TTM)
125
Return on Equity (TTM)
+5.1%
Current Ratio
3.6
EV/EBITDA (TTM)
38.8

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Recent insider buying suggests confidence in Novanta's future performance, indicating a belief in the company's growth potential.
  • Community sentiment has shifted positively, with discussions highlighting Novanta's innovative technologies and their applications in healthcare and industrial markets.
  • Analysts have noted Novanta's strong positioning in niche markets, which could lead to increased demand and revenue growth in the coming quarters.
  • Recent product launches have garnered attention, positioning the company as a leader in its field and attracting interest from potential clients.

Bear Case

  • Concerns have been raised about supply chain disruptions affecting Novanta's ability to meet demand, which could impact revenue projections.
  • Some community members express skepticism about the sustainability of recent growth, questioning whether it can be maintained in a competitive landscape.
  • Market sentiment remains cautious due to broader economic uncertainties, which could affect investor confidence in Novanta's stock.
  • Recent earnings reports have highlighted challenges in certain segments, leading to discussions about potential weaknesses in their business model.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

NOVT Latest News

NOVT Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NOVT.

Price Targets

Consensus target: $150.00

NOVT MoonshotScore

64/100

What does this score mean?

The MoonshotScore rates NOVT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: Matthijs Glastra

CEO

Matthijs Glastra serves as the CEO of Novanta Inc., bringing extensive experience in the technology and industrial sectors. His career includes leadership roles at various global companies, focusing on strategic growth and operational excellence. Glastra's background encompasses a strong understanding of engineering and business management, which he leverages to drive Novanta's innovation and market expansion. He is responsible for overseeing the company's overall strategy and performance, ensuring alignment with long-term growth objectives.

Track Record: Under Matthijs Glastra's leadership, Novanta Inc. has focused on expanding its presence in key markets and enhancing its product portfolio through strategic acquisitions and internal development. He has overseen the company's transition to a more integrated and customer-focused organization, driving improvements in operational efficiency and customer satisfaction. Glastra's tenure has been marked by a commitment to innovation and a focus on creating long-term value for shareholders.

What Investors Ask About Novanta Inc. (NOVT) — Technology

What does Novanta Inc. do?

Novanta Inc. designs, manufactures, and sells precision components and subsystems for original equipment manufacturers (OEMs) in the medical and industrial markets. The company operates through three segments: Photonics, Vision, and Precision Motion. These segments provide solutions ranging from laser scanning and beam delivery to medical-grade technologies and precision motion control. Novanta's products are used in diverse applications, including medical imaging, industrial automation, DNA sequencing, and laser processing. The company serves a global customer base through a direct sales force, resellers, distributors, and system integrators.

What do analysts say about NOVT stock?

Analyst consensus on Novanta Inc. (NOVT) reflects expectations for continued growth, driven by its diversified product portfolio and exposure to expanding medical and industrial markets. Key valuation metrics, such as the P/E ratio of 85.9, suggest a premium valuation, indicating high growth expectations. Analysts are closely monitoring the company's ability to maintain its gross margin of 44.4% and expand its profit margin. Revenue growth and strategic acquisitions are also key considerations. Analyst ratings vary, but generally reflect a positive outlook based on Novanta's market position and growth potential. No buy or sell recommendations are made.

What are the main risks for NOVT?

Novanta Inc. faces several risks, including potential economic downturns that could reduce OEM spending and demand for its products. Competition from established players and new entrants poses a threat to market share. Technological obsolescence requires continuous investment in research and development to maintain a competitive edge. Supply chain disruptions could affect production and delivery schedules. The company's high P/E ratio may indicate overvaluation, making the stock vulnerable to market corrections. These risks could impact Novanta's financial performance and stock price.

What are the key factors to evaluate for NOVT?

Novanta Inc. (NOVT) holds an AI score of 64/100 (moderate). P/E: 85.9x vs the S&P 500's ~20-25x. Analysts target $150.00 (-9%). Not financial advice.

How frequently does NOVT data refresh on this page?

NOVT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven NOVT's recent stock price performance?

Novanta Inc. (NOVT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across photonics, vision, and precision motion. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider NOVT overvalued or undervalued right now?

Novanta Inc. (NOVT) trades at 85.9x earnings. Analysts target $150.00 (-9%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

What research should beginners do before buying NOVT?

Before investing in Novanta Inc. (NOVT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
  • Financial metrics are as of the latest available reporting period.
Data Sources

Popular Stocks